Payment overview · 2025
General Payments
$143.37
8 reported records · 3 companies
Healthcare provider profile · identity verified
Robert A Chua, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TERRE HAUTE, IN · NPI 1184725442
Verified facts
What the public records show
CMS Open Payments records show Robert A Chua, M.D. received $143.37 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.28 | 40.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.73 | 39.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.36 | 20.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.37 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.28 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.73 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
200 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 981 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 606 | 139 |
| Alprazolam | Alprazolam | 589 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 115 |
| Omeprazole | Omeprazole | 370 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 85 |
| Gabapentin | Gabapentin | 351 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 96 |
| Furosemide | Furosemide | 308 | 81 |
| Lisinopril | Lisinopril | 303 | 67 |
| Famotidine | Famotidine | 290 | 76 |
| Metformin Hcl | Metformin Hcl | 235 | 63 |
| Carvedilol | Carvedilol | 233 | 55 |
| Trazodone Hcl | Trazodone Hcl | 231 | 53 |
| Potassium Chloride | Potassium Chloride | 227 | 50 |
| Ozempic | Semaglutide | 226 | 43 |
| Montelukast Sodium | Montelukast Sodium | 218 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 60 |
| Losartan Potassium | Losartan Potassium | 208 | 63 |
| Farxiga | Dapagliflozin Propanediol | 200 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 45 |
| Azithromycin | Azithromycin | 189 | 118 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 42 |
| Allopurinol | Allopurinol | 187 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 45 |
| Pregabalin | Pregabalin | 180 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 164 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 31 |
| Mounjaro | Tirzepatide | 158 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 63 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 141 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 39 |
| Ezetimibe | Ezetimibe | 126 | 41 |
| Topiramate | Topiramate | 125 | 25 |
| Prednisone | Prednisone | 124 | 76 |
| Meloxicam | Meloxicam | 119 | 29 |
| Eliquis | Apixaban | 118 | 21 |
| Ondansetron Odt | Ondansetron | 116 | 43 |
| Cefdinir | Cefdinir | 113 | 79 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 31 |
| Simvastatin | Simvastatin | 108 | 29 |
| Linzess | Linaclotide | 105 | 34 |
| Buspirone Hcl | Buspirone Hcl | 103 | 24 |
| Clonazepam | Clonazepam | 103 | 15 |
| Lidocaine | Lidocaine | 99 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 29 |
| Alendronate Sodium | Alendronate Sodium | 95 | 23 |
| Amoxicillin | Amoxicillin | 94 | 52 |
| Celecoxib | Celecoxib | 92 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 14 |
| Lorazepam | Lorazepam | 88 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 87 | 61 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 20 |
| Myrbetriq | Mirabegron | 84 | 19 |
| Jardiance | Empagliflozin | 82 | 21 |
| Sertraline Hcl | Sertraline Hcl | 81 | 14 |
| Spironolactone | Spironolactone | 76 | 21 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Glimepiride | Glimepiride | 74 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Fluconazole | Fluconazole | 71 | 38 |
| Donepezil Hcl | Donepezil Hcl | 68 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 25 |
| Vraylar | Cariprazine Hcl | 67 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 50 |
| Januvia | Sitagliptin Phosphate | 66 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 64 | 45 |
| Vascepa | Icosapent Ethyl | 63 | 14 |
| Meclizine Hcl | Meclizine Hcl | 61 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 41 |
| Ibuprofen | Ibuprofen | 59 | 15 |
| Methylprednisolone | Methylprednisolone | 59 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 17 |
| Klor-Con M20 | Potassium Chloride | 54 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 54 | 11 |
| Xarelto | Rivaroxaban | 54 | 11 |
| Methadone Hcl | Methadone Hcl | 53 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Cephalexin | Cephalexin | 48 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Levofloxacin | Levofloxacin | 47 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 31 |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Bumetanide | Bumetanide | 45 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 14 |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 15 |
| Kerendia | Finerenone | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Modafinil | Modafinil | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | 13 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Nystatin | Nystatin | 31 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Armodafinil | Armodafinil | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Ubrelvy | Ubrogepant | 29 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 14 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | 11 |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 20 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Selenium Sulfide | Selenium Sulfide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.37 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Korlym, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error